Tesamorelin: How It Works, Uses, and Side Effects

Tesamorelin is a synthetic growth-hormone-releasing hormone (GHRH) analog that signals the pituitary gland to release the body's own growth hormone (GH). It is FDA-approved as Egrifta to reduce excess abdominal fat in adults with HIV-associated lipodystrophy [1]. It is also used off-label and in compounded form for body-composition and healthy-aging goals; these uses are currently being studied and should only happen under licensed clinician supervision.

What is tesamorelin?

GHRH analog basics

Tesamorelin is a 44-amino-acid synthetic peptide that mimics the body's natural growth-hormone-releasing hormone (GHRH). GHRH is made in the hypothalamus and tells the pituitary gland — a pea-sized gland at the base of the brain — to release growth hormone (GH). Tesamorelin binds GHRH receptors on the pituitary and prompts a pulsed release of the body's own GH [1].

Because tesamorelin stimulates your own pituitary rather than replacing GH directly, GH output still follows the body's natural feedback loops. That is different from injecting recombinant human growth hormone (rhGH), which bypasses those signals entirely.

Brand name vs compounded tesamorelin

The FDA-approved brand is Egrifta, marketed in the U.S. as Egrifta SV and, more recently, the once-weekly formulation Egrifta WR [1]. Tesamorelin is also available as a compounded medication through licensed 503A pharmacies — state-licensed pharmacies that prepare prescriptions for individual patients based on a clinician's order. Compounded versions are not FDA-approved products and are not interchangeable with Egrifta; quality depends on the pharmacy's standards and the clinician overseeing care. For more on how 503A pharmacies operate, see our guide to compounded peptides.

How does tesamorelin work in the body?

Pituitary stimulation and GH release

After a subcutaneous injection, tesamorelin reaches the pituitary and binds GHRH receptors, triggering a natural-feeling pulse of GH into the bloodstream [1]. Its plasma half-life is roughly 26 to 38 minutes, so the drug itself clears quickly, but the downstream hormonal effects last much longer [1].

Effect on IGF-1

Growth hormone signals the liver to produce insulin-like growth factor 1 (IGF-1), the hormone responsible for many of GH's downstream effects on tissue, fat, and muscle. In clinical trials, tesamorelin raised IGF-1 levels by an average of roughly 80% over baseline [2]. Clinicians monitor IGF-1 to make sure levels stay within a safe range, because chronically elevated IGF-1 carries theoretical risks discussed below.

What is tesamorelin approved and used for?

FDA-approved use in HIV lipodystrophy

Tesamorelin's only FDA-approved indication is the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy — a condition where antiretroviral therapy can cause a build-up of visceral adipose tissue (VAT), the deep belly fat that wraps around organs [1]. In the pivotal phase 3 trials, patients lost roughly 15–18% of visceral fat over 26 weeks compared with placebo, with some participants experiencing side effects including injection-site reactions, joint pain, and small rises in blood glucose [2][3].

Off-label and longevity uses

Outside of HIV lipodystrophy, tesamorelin is currently being studied for visceral fat reduction in people with non-alcoholic fatty liver disease (NAFLD) and HIV [4], and is used off-label by some clinicians for body-composition and healthy-aging goals. These uses are not FDA-approved, and the evidence base is much smaller than for the approved indication. The same side effects and contraindications apply regardless of why the medication is prescribed.

What benefits do people report, and what trade-offs come with them?

Visceral fat reduction

The strongest evidence is for reducing visceral fat. In two pivotal 26-week placebo-controlled trials, tesamorelin reduced VAT by about 15% on average, measured by CT scan [2][3]. Visceral fat is the type most linked to cardiometabolic risk, so the effect is meaningful — but the same trials show that visceral fat returns when tesamorelin is stopped, and the benefit is paired with side effects including joint pain, fluid retention, and rising IGF-1 that must be monitored [1][2]. Individual results vary.

Body composition and metabolic markers

In the same trials, participants saw small improvements in triglycerides and the cholesterol-to-HDL ratio, and modest reductions in liver fat in follow-up NAFLD studies [4]. These metabolic improvements occurred alongside increases in fasting blood glucose and reduced insulin sensitivity in some participants [1][2], which is why glucose monitoring is part of standard follow-up. Subjective effects some people report — better sleep, more energy, faster recovery — are not consistently demonstrated in controlled trials, and individual results vary.

What side effects and risks should I know about?

Common side effects

The most common side effects reported in clinical trials were [1][2]:

• Injection-site reactions (redness, itching, bruising)
• Joint pain (arthralgia) and muscle pain (myalgia)
• Swelling in the hands and feet (peripheral edema)
• Tingling or numbness (paresthesia)
• Headache, nausea, and rash
• Increases in fasting blood glucose and reduced insulin sensitivity

Serious risks and contraindications

Tesamorelin's prescribing information includes warnings about [1]:

• Increased IGF-1 — clinicians monitor levels and adjust care if IGF-1 climbs above the normal range.
• Glucose intolerance and worsening diabetes — fasting glucose and HbA1c should be checked before and during use.
• Fluid retention, including carpal tunnel-like symptoms.
• Hypersensitivity reactions, including rare anaphylaxis.

Tesamorelin is contraindicated in pregnancy, in people with disruption of the hypothalamic-pituitary axis (for example from surgery, radiation, or trauma), and in people with active malignancy [1]. Because GH and IGF-1 can theoretically promote the growth of existing cancer cells, any current cancer must be evaluated before considering this therapy. Discuss your full medical history with a clinician before starting.

How is tesamorelin dosed and administered?

Typical dose and injection site

In the pivotal trials of the original daily formulation, the studied dose was approximately 2 mg given as a subcutaneous injection once daily, usually into the abdomen [1][2]. The newer once-weekly Egrifta WR formulation uses a different schedule. Exact dosing — including starting dose, timing, and any adjustments — is determined by your prescribing clinician based on labs and tolerance. This article does not provide individual dosing instructions.

Storage and handling

Tesamorelin is a peptide and is sensitive to heat and light. Egrifta is supplied as a lyophilized (freeze-dried) powder that must be reconstituted before use and refrigerated according to the label [1]. Your clinician or pharmacist will walk through reconstitution, injection technique, and safe sharps disposal.

How does tesamorelin compare to other peptides?

Tesamorelin is often discussed alongside other GH-stimulating peptides. Here is a high-level comparison — none of these are interchangeable, and only tesamorelin is FDA-approved. All carry potential side effects; only tesamorelin has been studied in large controlled trials. For a wider overview, see our guide to longevity peptides.

Tesamorelin vs sermorelin

Sermorelin is a shorter GHRH fragment (the first 29 amino acids of GHRH). Tesamorelin is a stabilized 44-amino-acid analog with a longer biological effect on IGF-1 and the strongest clinical-trial evidence for visceral fat reduction [2]. Sermorelin is no longer an FDA-approved product and is only available through compounding.

Tesamorelin vs CJC-1295/ipamorelin

CJC-1295 and ipamorelin are commonly stacked in off-label peptide protocols. Neither is FDA-approved, and there are no large randomized trials of either in humans for body composition or longevity. Tesamorelin has been studied in thousands of patients in controlled trials [2][3]; trade-offs include higher cost and, in the original formulation, daily injection.

How is tesamorelin combined with other peptides?

Some clinicians and patients ask about pairing tesamorelin with other peptides in off-label protocols. There are no large, FDA-reviewed combination studies, so any stacking is exploratory and should only happen under clinician supervision with appropriate lab monitoring. Combinations are currently being studied and are not endorsed here as treatment recommendations.

Tesamorelin with ipamorelin (GHRH + GHRP)

The most discussed pairing is a GHRH analog like tesamorelin with a growth-hormone-releasing peptide (GHRP) like ipamorelin. The two act on different receptors — tesamorelin on GHRH receptors and ipamorelin on ghrelin receptors — which can theoretically produce a larger GH pulse than either alone [5]. The trade-off: side effects (fluid retention, joint pain, glucose changes) and IGF-1 elevation may stack as well, and there is no controlled human trial data for tesamorelin + ipamorelin specifically. Active cancer and pregnancy remain contraindications regardless of the combination [1].

Tesamorelin with CJC-1295

Combining tesamorelin with CJC-1295 — another GHRH analog — is generally not recommended, because both drugs act on the same receptor and would not add benefit while potentially compounding side effects. Off-label protocols that include CJC-1295 typically pair it with a GHRP like ipamorelin instead of with tesamorelin.

Tesamorelin with GLP-1 medications

Some patients use tesamorelin alongside GLP-1 medications such as semaglutide or tirzepatide to address visceral fat while losing overall weight. These drugs work through entirely different pathways — GLP-1s reduce appetite and improve glucose control, while tesamorelin acts on the GH/IGF-1 axis — so there is no known pharmacologic conflict. However, tesamorelin can raise fasting glucose [1] while GLP-1s lower it, so glucose monitoring is especially important. There are no large trials of this combination, and it should only be considered as part of a clinician-supervised plan.

What to monitor with any combination

Regardless of the stack, the same safety markers matter: IGF-1, fasting glucose and HbA1c, lipids, blood pressure, and symptoms of fluid retention. A clinician should set a baseline, recheck labs on a schedule, and adjust or stop therapy if IGF-1 climbs above the normal range or glucose worsens [1]. Adding more peptides does not change the underlying contraindications — pregnancy, active malignancy, and pituitary axis disruption still apply.

Who should not take tesamorelin?

Tesamorelin is not appropriate for everyone. According to the FDA label, it should not be used in [1]:

• People who are pregnant or trying to become pregnant.
• People with active malignancy (any current cancer).
• People with disruption of the hypothalamic-pituitary axis from surgery, radiation, trauma, or certain tumors.
• People with a known hypersensitivity to tesamorelin or mannitol (a component of the formulation).
• Children — safety and efficacy in pediatric patients have not been established.

People with diabetes, pre-diabetes, or a strong personal or family history of cancer should have a careful conversation with their clinician about whether the potential benefits outweigh the risks. Discuss your full medical history with a clinician before starting.

How do you get tesamorelin and what does it cost?

Tesamorelin is a prescription-only injectable. To get it, you need a clinical evaluation — typically including a medical history review, baseline labs (IGF-1, fasting glucose or HbA1c, lipids), and a discussion of goals and risks. From there, a licensed clinician can decide whether tesamorelin is appropriate and, if so, prescribe either the brand-name Egrifta or a compounded formulation from a licensed 503A pharmacy. Eligibility is determined by clinical evaluation.

Brand-name Egrifta out-of-pocket cash prices commonly run into the thousands of dollars per month, and insurance coverage is generally limited to the FDA-approved HIV lipodystrophy indication. Compounded tesamorelin is typically less expensive but is not FDA-approved and quality varies by pharmacy.

Several licensed telehealth providers offer clinician-reviewed access to peptide therapies. Chia is one such option — a telehealth platform that provides clinical evaluations for compounded GLP-1s and longevity peptides where clinically appropriate. As with any peptide, the most important factor is that a licensed clinician is reviewing your labs and history.

Frequently asked questions

Keep reading

Longevity Peptides

Sermorelin: How This Growth Hormone Peptide Works

Peptides

CJC-1295: the long-acting GHRH analogue — 2026 evidence-based guide

Peptides

Sermorelin: the original GH-releasing peptide — 2026 evidence-based guide